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o r i g i n a l a r t i c l e
Effectiveness of Screening Hospital Admissions to Detect
Asymptomatic Carriers of Clostridium difficile :
A Modeling Evaluation
Cristina Lanzas, PhD;1 Erik R. Dubberke, MD2
objective. Both asymptomatic and symptomatic Clostridium difficile carriers contribute to new colonizations and infections within a
hospital, but current control strategies focus only on preventing transmission from symptomatic carriers. Our objective was to evaluate
the potential effectiveness of methods targeting asymptomatic carriers to control C. difficile colonization and infection (CDI) rates in a
hospital ward: screening patients at admission to detect asymptomatic C. difficile carriers and placing positive patients into contact precautions.
methods. We developed an agent-based transmission model for C. difficile that incorporates screening and contact precautions for
asymptomatic carriers in a hospital ward. We simulated scenarios that vary according to screening test characteristics, colonization prevalence,
and type of strain present at admission.
results. In our baseline scenario, on average, 42% of CDI cases were community-onset cases. Within the hospital-onset (HO) cases,
approximately half were patients admitted as asymptomatic carriers who became symptomatic in the ward. On average, testing for
asymptomatic carriers reduced the number of new colonizations and HO-CDI cases by 40%–50% and 10%–25%, respectively, compared
with the baseline scenario. Test sensitivity, turnaround time, colonization prevalence at admission, and strain type had significant effects
on testing efficacy.
conclusions. Testing for asymptomatic carriers at admission may reduce both the number of new colonizations and HO-CDI cases.
Additional reductions could be achieved by preventing disease in patients who are admitted as asymptomatic carriers and developed CDI
during the hospital stay.
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Clostridium difficile is an important nosocomial pathogen that
causes diarrhea, pseudomembranous colitis, and possibly
death. The incidence, mortality, and medical care cost of C.
difficile infection (CDI) have reached historic highs. In the
United States, the number of discharges in which the patient
was diagnosed with CDI doubled from 2000 to 2009; C. dif-
ficile is estimated to cause as many as 250,000 new infections
and 14,000 deaths per year, and in US acute care facilities
alone, the cost is as much as $3.2 billion per year.1-5 In the
latest report on antibiotic resistance threats in the United
States released by the Centers for Disease Control and Pre-
vention in 2013, C. difficile was classified within the highest
threat level of urgent.5 The increase in C. difficile infection
rates is attributed partially to the emergence of the epidemic
NAP1/B1/027 strain, which has high levels of toxin A and B
production and carries the binary toxin.6-8 Despite the burden
and threat posed by C. difficile, CDI prevention has changed
little in recent decades. Current control strategies rely on
limiting the spread of C. difficile from symptomatic patients.
Therefore, patients with diarrheal stool are tested for C. dif-
ficile, and if the patient tests positive, isolation and contact
precaution measures are applied.9 To more effectively contain
C. difficile, there is a critical need to identify additional control
strategies.
Using highly discriminatory typing methods, recent epi-
demiological studies have challenged the notion that symp-
tomatic patients are the main contributors to C. difficile trans-
mission.10-12 Similarly, Curry et al12 found that CDI cases were
as frequently linked to transmission from asymptomatic as
to symptomatic patients. Therefore, the contribution of
symptomatic cases to transmission and new infection is likely
to be lower than previously thought. In addition, the likeli-
hood of transmission and infection appears to also be strain
specific. In a recent hospital ward–based transmission study,
only 19% of cases were traced to other known CDI cases;
however, for the epidemic strain NAP1/B1/027, up to 63%
of cases were traced to other CDI cases.11 Consequently, CDI
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Patients colonized with 027
at admission, %
Baseline NA NA 10 20
Diagnostic tests scenarios 0.75, 0.90, 0.99 0.5, 1, 2.5 10 20
Colonization at admission scenarios 0.90 1 5, 10, 20, 30 20
Strain carriage at admission 0.90 1 10 0, 10, 20, 30, 40
note. NA, not applicable.
figure 1. Model outcomes for the baseline scenario (no testing for asymptomatic carrier detection). A, Number of new colonizations
(Col), total Clostridium difficile infection (CDI) cases, hospital-onset CDI cases (HO-CDI), and community-onset CDI cases (CO-CDI)
per 1,000 admissions. B, Proportion of CO-CDI cases, HO-CDI cases who were not already colonized at the ward (HO-CDI new), and
HO-CDI cases who were admitted as colonized and developed CDI within the ward (HO-CDI col). The middle line in the box represents
the median, and upper and lower areas of the box indicate the seventy-fifth and twenty-fifth percentiles.
might be more effectively controlled by targeting additional
sources of C. difficile transmission beyond clinical cases.
Asymptomatic colonization prevalence for C. difficile
among admitted patients has been reported to be up to
20%,6,13,14 and admitted colonized patients may play an im-
portant role in sustaining C. difficile transmission in acute
healthcare facilities. Therefore, preventing secondary infec-
tion transmission from asymptomatic colonized patients can
be an additional control point to decrease CDI burden in
hospitals.15 For other nosocomial pathogens, such as meth-
icillin-resistant Staphylococcus aureus, universal screening at
admission has resulted in reduced rates of hospital-acquired
infections.16 Recent advances in diagnostic testing for C. dif-
ficile have encouraged the evaluation of the feasibility of
screening patients at admission for C. difficile and subsequent
application of isolation precautions.17-19 An outcome model
identified C. difficile screening, coupled with isolation pre-
cautions, as a cost-effective intervention when the proportion
of admitted patients with C. difficile colonization was greater
than approximately 10%.20
For healthcare-associated infections, computational models
of pathogen transmission have become valuable tools to eval-
uate healthcare interventions, especially in the absence of
controlled intervention studies.21 In this study, we evaluated
the effect of screening patients for C. difficile colonization at
admission—followed by contact precautions for patients who
tested positive—on preventing colonization and disease in an
endemic setting. We used an agent-based model of C. difficile
transmission to specifically address how diagnostic test char-
acteristics (ie, sensitivity and turnaround time) used for
screening, colonization prevalence, and type of strain carried
by colonized patients at admission affected the effectiveness
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figure 2. Effects of test sensitivity and turnaround time on the mean number (95% confidence interval) of new colonizations (A) and
hospital-onset Clostridium difficile infection (HO-CDI) cases per 1,000 admissions (B) when screening for asymptomatic carriers and
isolation precautions are applied, with colonization prevalence on admission of 10%.
of screening for asymptomatic carriers in reducing trans-




We developed an agent-based model for the transmission of
C. difficile in a hospital ward. Electronic data were collected
retrospectively from 6 medicine wards at Barnes-Jewish Hos-
pital in St. Louis, Missouri, from January 1 through December
31, 2008, using the hospital’s medical informatics databases.
The data set included 11,046 admissions. The mean age of
patients was 57 years, and 54% of patients were female, with
a mean Charlson comorbidity score of 1.8. The model follows
the conceptual modeling framework presented by Lanzas et
al15 and incorporates a more detailed description of antibiotic
exposure, type of C. difficile strain, screening, and contact
precautions.
Because a higher proportion of patients who acquire the
epidemic strain NAP1/B1/027 develop CDI compared with
other strains,6,11 the model was expanded to include 2 strain
groups: epidemic strain NAP1/B1/027 (027 group) and other
strains (non-027 group). We expanded the model to consider
screening at admission in the following way: patients iden-
tified as asymptomatic carriers at admission would be placed
in contact precautions. Patients in isolation were assumed to
remain in the same ward they were in. Additional information
is available directly from the authors regarding the overview,
design concepts, and details protocol, a suggested standard-
ized protocol to describe agent-based models.22 We imple-
mented the model in NetLogo (ver. 5.0), an open-source,
agent-based modeling tool.
Scenarios
Table 1 summarizes evaluated intervention scenarios. The
baseline scenario represents current control strategies (ie, only
patients with diarrheal stools are tested for the presence of
C. difficile toxin). We evaluated scenarios that varied by the
sensitivity and turnaround time of the diagnostic tests avail-
able to identify asymptomatic colonized patients. Test spec-
ificity was assumed to be 100%. Polymerase chain reaction–
based tests have reasonable sensitivity and reduced turnover
time compared with other methods, such as the cytotoxicity
cell assay, and therefore have the potential to be used for
screening at admission. On the basis of published validation
studies for diagnostic polymerase chain reaction tests for C.
difficile, the scenarios differed in test sensitivity to detect
asymptomatic carriers (0.75, 0.90, and 0.99) and in turna-
round time (0.5, 1, and 2.5 days).17,18,23 Test sensitivity and
turnaround time were evaluated in a factorial-like design. The
baseline value for the efficacy of contact precautions was con-
servatively set to 75% to account for the fact that imple-
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figure 3. Effects of colonization prevalence at admission on the mean number (95% confidence interval) of new colonizations (A)
and hospital-onset Clostridium difficile infection (HO-CDI) cases for 1,000 admissions (B). Assumed screening sensitivity, 0.90; turnaround
time, 1 day.
mentation of and adherence to control measures may not
necessarily be perfect.24
Additional factors that may influence the efficacy of the
interventions are the colonization prevalence at admission
and the type of strain the colonized patients carried at ad-
mission (Table 1). Model outcomes include the number of
C. difficile colonizations and total CDI cases per 1,000 ad-
missions. The use of an agent-based model allows us to track
individual timelines for infection and disease of each simu-
lated patient. We divided the CDI cases into the number of
community-onset (CO) cases and the number of HO cases.
For the HO cases, we tracked whether the patient was col-
onized and developed CDI within the ward or was admitted
as colonized and subsequently developed CDI at the hospital.
When 2 variables were varied simultaneously in the simu-
lations, their effects on the model outcomes were evaluated
using a 2-way ANOVA analysis. Analysis of the model output
was carried out in R 2.15 (R Development Core Team).
results
The model outcomes for the listed scenarios in Table 1 are
presented in Figures 1–4. At the baseline scenario (ie, no
testing to detect asymptomatic carriers), the total number of
CDI cases per 1,000 admissions was highly variable, with a
mean of 24.7 and a standard deviation of 4.18 (Figure 1A).
The number of new colonizations was 100 per 1,000 admis-
sions, with a standard deviation of 13.19. On average, 58%
of CDI cases were HO cases, for a mean of 14.5 per 1,000
admissions. Approximately half of the HO-CDI cases were
patients admitted colonized who became diseased in the ward
(Figure 1B).
Applying admission testing with reasonable test sensitivity
(greater than 0.75) and turnaround time (less than 2.5 days)
decreased new colonizations by a mean of 40% to 60.15 per
1,000 admissions (interquartile range [IQR], 18.82 per 1,000
admissions). HO-CDI cases were reduced by 19% to 11.70
per 1,000 admissions (IQR, 3.95 per 1,000 admissions) com-
pared with the baseline scenario (Figure 2). For the best-case
scenario (sensitivity, 0.99; turnaround time, 0.5 days), the
mean numbers of new colonizations and HO-CDIs were re-
duced by approximately 52% (48 cases per 1,000 admissions)
and 25% (10.8 cases per 1,000 admissions), respectively (Fig-
ure 2). Both test sensitivity and turnaround time had an
overall significant effect on both new colonizations and HO-
CDI cases (Figure 2). The scenario with a sensitivity of 0.99
and a turnover of 2.5 days had a slightly high number of
HO-CDI cases compared with the scenario with a sensitivity
of 0.90 and a turnover of 2.5 days (mean, 11.77 vs 11.86
cases per 1,000 admissions); the difference was not found to
be statistically significant.
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figure 4. Effects of 027 strain prevalence at admission on the mean number (95% confidence interval) of hospital-onset Clostridium
difficile infection (HO-CDI) cases per 1,000 admissions (A) and HO-CDI cases caused by 027 per 1,000 admissions (B). Assumed screening
sensitivity, 0.90; turnaround time, 1 day.
We further evaluated the effect of testing at different col-
onization prevalences (Figure 3) and whether the relative pro-
portion of admitted colonized patients with 027 versus other
strains affected testing efficacy (Figure 4). Assuming a screen-
ing sensitivity of 0.90 and a turnaround time of 1 day, ap-
plying testing coupled with contact precautions reduced new
colonizations by approximately 42% and HO-CDI cases by
14%–24%, depending on colonization prevalence at admis-
sion. There was a significant interaction between the colo-
nization prevalence at admission and the testing efficacy in
reducing both new colonizations and HO-CDI cases. The
number of patients needed to screen at admission to prevent
1 colonization event or 1 clinical case within a year are pre-
sented in Table 2.
As the percentage of admitted patients colonized with 027
increased, the model predicted an increase in the number of
HO-CDI cases (Figure 4). The efficacy of testing remained
fairly constant at a 20% reduction of HO-CDI cases, despite
the increase in admitted patients colonized with 027 for a
given prevalence. The proportion of HO-CDI cases caused
by 027 was greater than the proportion of admitted colonized
patients with 027. When 027 was responsible for 20% of the
admitted colonized patients, the resultant simulation pre-
dicted that the number of HO-CDI cases caused by 027 would
be approximately 50%.
discussion
Evidence-supported strategies to prevent C. difficile infection
are limited to the use of gloves when caring for patients with
CDI and antimicrobial stewardship.9,25 The application of
these strategies and other suggested measures, such as en-
vironmental decontamination, have resulted in modest re-
ductions in CDI incidence in endemic settings.26 Thus, further
research to identify additional sources of CDI and novel con-
trol strategies are necessary. We previously used the same
modeling framework to evaluate the contribution of asymp-
tomatic carriers and CDI patients to new colonizations at the
ward level.15 Our results indicated that admission of asymp-
tomatic carriers highly influenced C. difficile outcomes and
underscored the need to further evaluate the role of asymp-
tomatic colonized patients. Recent epidemiological studies
have also shown that in addition to CDI patients, asymp-
tomatic carriers and unknown sources of C. difficile are im-
portant contributors to new CDI cases.10-12,27
Patients can develop CDI through 3 different infection
histories: they can be admitted with CDI (CO-CDI), be ad-
mitted as colonized patients and become diseased during the
hospital stay, or become both colonized and diseased patients
during the hospital stay. Preventing CDI for these different
timelines likely requires different prevention strategies (eg,
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S1 5 20 28.71 (26.55–30.87) 35 (32–38) 2.04 (1.37–2.71) 490 (369–730)
S2 10 20 43.14 (40.98–45.3) 23 (22–24) 2.93 (2.26–3.61) 341 (277–442)
S3 20 20 55.74 (53.58–57.90) 18 (17–19) 3.86 (3.18–4.54) 259 (220–314)
S4 30 20 58.94 (56.78–61.10) 17 (16–18) 4.43 (3.75–5.10) 225 (196–267)
S5 10 0 42.52 (40.10–44.93) 24 (22–25) 2.01 (1.41–2.62) 498 (382–709)
S6 10 10 42.8 (40.39–45.22) 23 (22–25) 2.52 (1.91–3.12) 397 (321–524)
S7 10 20 40.63 (38.21–43.05) 25 (23–26) 2.73 (2.12–3.33) 366 (300–472)
S8 10 30 42.81 (40.40–45.23) 23 (22–25) 3.41 (2.80–4.02) 293 (249–357)
S9 10 40 41.6 (39.18–44.02) 24 (23–26) 3.73 (3.13–4.34) 268 (230–319)
note. Data are means (95% confidence intervals), unless otherwise indicated, of decrease achieved with testing at admission and
their associated number needed to treat (NNT) for the scenarios in which the colonization prevalence was varied (S1–S4) and the
prevalence of the 027 strain at admission was varied (S5–S9). The NNT indicates the number of admitted patients who would need
to be tested at admission in order to prevent 1 colonization or HO-CDI event.
preventing colonization vs preventing CDI in those patients
already colonized); the different pathways may help explain
why current strategies appear to have a floor effect, since they
focus mostly on reducing secondary cases from symptomatic
patients.25,28,29 In our baseline scenario, patients who became
colonized and diseased within the hospital ward represented,
on average, 50% of the possible HO-CDI cases. Those col-
onized on admission have been considered to be at lower risk
for subsequent onset of disease than those not colonized.30
However, emerging data suggest that this may no longer be
the case.6,31 Of note, if asymptomatic carriage of C. difficile
does maintain a protective effect against CDI and fewer than
50% of HO-CDI cases are from patients colonized on ad-
mission, the efficacy of testing should be even greater than
found in this study. Given the prevalence of patient coloni-
zation at admission, these patients represent an important
source of HO-CDI, and approaches to prevent disease in
patients who are already colonized at admission are necessary.
In the different simulated scenarios, testing was highly ef-
fective in reducing colonization events. However, the scope
of the model—the hospital ward—does not allow us to fully
assess the implications of reducing colonization rates within
the ward. A reduced colonization rate could result in an over-
all reduction in the disease burden in healthcare networks
beyond the ward. Patients who become colonized at the ward
level could develop CDI at the community level or at other
healthcare settings, such as nursing homes, or be readmitted
and develop HO-CDI in future hospital visits. Elderly patients
and residents of long-term care facilities are disproportionally
affected by CDI because of their inherent susceptibility, fre-
quent hospitalization, and exposure to antimicrobials; there-
fore, they could particularly benefit from a reduced proba-
bility of colonization during their multiple readmissions in
hospitals. Models that represent a full healthcare network are
necessary to evaluate the implications of reducing hospital C.
difficile transmission beyond the hospital level. Testing for
asymptomatic carriers at admission can reduce both the num-
ber of new colonizations and CDI cases. Additional reduc-
tions could be achieved by preventing disease in patients who
are admitted as asymptomatic carriers and might develop CDI
during the hospital stay. In our current model, we assumed
that it was feasible to establish contact precautions for all
patients identified as C. difficile carriers in the ward. However,
for hospital wards with shared rooms, complete compliance
may not be feasible.
Screening patients at admission to detect and isolate
asymptomatic carriers could decrease the number of new
colonizations and HO-CDI cases at the ward level. In our
various scenarios, screening patients, coupled with isolation
precautions, reduced the number of new colonizations up to
50% and the number of HO-CDI cases up to 25%, approx-
imately. These values agree with the predicted transmission
events associated with asymptomatic carriers in our previous
modeling study.15 We specifically evaluated the efficacy of this
strategy when test characteristics and proportion of colonized
patients at admission were varied. Our simulations indicated
that tests with a sensitivity greater than 90% and turnaround
times less than 2.5 days could reduce the number of secondary
new colonizations (and subsequent CDIs) caused by asymp-
tomatic carriers. Although screening for asymptomatic C. dif-
ficile colonization appears promising on the basis of these
simulations, additional research is needed to determine the
costs, feasibility, and impact of screening on patient out-
comes. In addition, the use of the model to support policy
recommendations will require the assessment of the model
performance in other populations, since the parameters and
assumptions are specific to the setting in which the data that
informed the model were collected (ie, adults on medical
wards). For example, parameters such as discharge rates or
ability to mount immune response after colonization are pop-
ulation specific.
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